CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma

Table 2 Proportion of all patients and patients with recurrence/metastasis and CD44/CD24 data with CD44⁺/CD24^-/low tumor cells

	n	All cases (%)	P	n	Recurrence/metastatic cases (%)	P*
Age (years)
< 50	74	18.34 ± 2.70	0.444	34	24.91 ± 3.79	0.022
≥ 50	73	15.45 ± 2.66		38	13.20 ± 3.32
Tumor size
T1	47	15.78 ± 2.86	0.224	15	13.19 ± 3.53
T2	76	20.12 ± 2.90		44	23.78 ± 3.68
T3 + T4	17	10.27 ± 4.46		13	11.83 ± 6.60	0.152
Lymph node involvement
Absent	32	8.66 ± 2.70	0.026	18	10.00 ± 3.77	0.075
Present	115	19.20 ± 2.29		54	21.53 ± 3.19
TNM stage
I + II	70	15.87 ± 2.63	0.500	33	16.88 ± 3.74	0.368
III + IV	77	18.49 ± 2.81		39	21.73 ± 3.79
ER expression
Negative	90	16.49 ± 2.47	0.845	47	18.92 ± 3.17	0.944
Positive	57	17.26 ± 3.07		25	19.32 ± 4.81
PR expression
Negative	83	13.09 ± 2.41	0.038	43	14.63 ± 3.06	0.046
Positive	64	21.06 ± 2.98		29	25.32 ± 4.51
Her2 expression
Negative	77	16.18 ± 3.03	0.566	38	17.36 ± 4.17	0.441
Positive	70	18.47 ± 2.61		34	21.57 ± 3.47
Basal-like feature ^†
Absent	108	18.44 ± 2.24	0.143	49	11.70 ± 4.07	0.050
Present	39	11.93 ± 3.66		23	22.66 ± 3.30
Recurrence or metastasis
Absent	75	14.26 ± 2.72	0.246
Present	72	18.73 ± 2.58
Lesions in recurrence/metastatic patients
Primary				56	15.39 ± 2.63	0.014
Secondary				16	30.41 ± 6.46

* Calculated by t tests. ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2.
^† Immunohistochemically negative for both SR and Her2.

ISSN: 1756-9966